Research & Development

ERX Pharmaceuticals is focused on the discovery and development of innovative drugs for the treatment of obesity and related diseases. ERX-1000, ERX’s lead drug candidate, is a first-in-class leptin sensitizer in Phase 1 clinical trials for the treatment of obesity. The research and development pipeline also includes preclinical and discovery stage candidates, including ERX-2000 for diabetes.

Targeting Leptin Resistance

ERX is developing first-in-class leptin sensitizers as a therapeutic approach to overcome the state of leptin resistance in obesity and related diseases.


dna-outline-94Created with Sketch.

Pipeline

ERX is focused on the discovery and development of innovative drugs for the treatment of obesity and related diseases, with a pipeline of clinical stage, preclinical, and discovery stage candidates.
Counter – OutlineCreated with Sketch.

ERX-1000 for Obesity

ERX-1000, a first-in-class leptin sensitizer, is in development for the treatment of obesity and related diseases. A first-in-human Phase 1 clinical trial of ERX-1000 has shown generally well tolerated, dose responsive weight loss in a 4-week treatment period, thereby yielding initial proof of efficacy in people with obesity.

Future Development Candidates

ERX’s product pipeline includes the lead clinical candidate ERX-1000, as well as other leptin sensitizers that exhibit differentiated properties.


Learn More About ERX’s Research Efforts


Articles and Publications

A great deal of research into leptin and leptin sensitization has been completed since the discovery of the leptin hormone in 1994. Previous research pointing to leptin resistance as a driver of obesity has helped inform our approach.


VIEW A SELECTION OF ARTICLES AND RESEARCH PUBLICATIONS ON LEPTIN